Tyra Bioscience, Inc (TYRA)

Tyra Biosciences reported Q1 and Q2 2025 financial results, with Q2 EPS exceeding expectations. The company announced the first patient dosing in the Phase 2 SURF302 clinical trial of TYRA-300 for bladder cancer and the first child dosed in BEACH301 for pediatric achondroplasia. Tyra Biosciences participated in investor events, including the Bank of America Global Healthcare Conference and the H.C. Wainwright 27th Annual Global Investment Conference. Wall Street analysts have given TYRA a "Strong Buy" consensus rating with a 12-month stock price target of $30.71. Over the last six months, TYRA stock has seen a 42.44% rise.

As a clinical-stage biotechnology company, Tyra Biosciences, Inc. does not currently have products generating sales revenue, and therefore, there is no discernible demand seasonality.

Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines for cancer and genetically defined conditions, utilizing its proprietary SNÅP platform. The company operates in the Health Technology sector, specifically in Drug Discovery, targeting Fibroblast Growth Factor Receptor (FGFR) biology. Its major product candidates include TYRA-300, an oral, selective FGFR3 inhibitor for bladder cancer and skeletal dysplasias; TYRA-200, an oral, selective FGFR2 inhibitor for intrahepatic cholangiocarcinoma and other solid tumors; and TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers.

Tyra Biosciences, Inc. is headquartered in Carlsbad, California, United States, and conducts clinical trials across multiple U.S. sites.

Tyra Biosciences has supported the Bladder & Kidney Cancer Academy, demonstrating its commitment to advancing urologic oncology. Positive analyst ratings and consistent participation in investor events also contribute to a favorable perception.

Tyra Biosciences, Inc. has a mixed ownership structure including institutional, insider, and public/individual investors. Institutional ownership increased to 106.0% as of June 2025. Major institutional owners include Ra Capital Management, L.P., and Alta Partners Management Company, L.P. Insiders hold approximately 50.21% of the company's stock.